Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Previously Treated ◽

Versus Treatment

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30313-3 ◽

2017 ◽

Vol 18 (6) ◽

pp. 743-754 ◽

Cited By ~ 144

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio Gonzalez Martin ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽

Versus Treatment

PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab PLUS Capecitabine and Capecitabine ALONE in Turkey

Value in Health ◽

10.1016/j.jval.2020.08.241 ◽

2020 ◽

Vol 23 ◽

pp. S441

Author(s):

B. Akyol Ersoy ◽

E. Erdogan-Ciftci ◽

L. Yanik ◽

B. Guler ◽

G. Ozcan ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Cost Utility ◽

Trastuzumab Emtansine ◽

Utility Model ◽

Her2 Positive ◽

ADCs Approved for Use: Trastuzumab Emtansine (Kadcyla®, T-DM1) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Antibody-Drug Conjugates ◽

10.1002/9781119060727.ch14 ◽

2016 ◽

pp. 345-380 ◽

Cited By ~ 1

Author(s):

Gail D. Lewis Phillips ◽

Sanne de Haas ◽

Sandhya Girish ◽

Ellie Guardino

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC)

Annals of Oncology ◽

10.1016/s0923-7534(20)34362-3 ◽

2012 ◽

Vol 23 ◽

pp. ixe5-ixe6 ◽

Cited By ~ 1

Author(s):

S. Verma ◽

D. Miles ◽

L. Gianni ◽

I. Krop ◽

M. Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3

Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study

10.1158/1538-7445.sabcs15-p4-14-01 ◽

2016 ◽

Author(s):

V Diéras ◽

D Miles ◽

S Verma ◽

M Pegram ◽

M Welslau ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Evaluating The Clinical Effectiveness of Trastuzumab Emtansine (T-DM1) Versus All Other Treatments For Previously Treated, Unresectable, HER2-Positive Metastatic Breast Cancer (MBC): A Mixed Treatment Comparison (MTC)

Value in Health ◽

10.1016/j.jval.2017.08.108 ◽

2017 ◽

Vol 20 (9) ◽

pp. A416

Author(s):

N Paracha ◽

N Irahara ◽

C Schuhmacher

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Clinical Effectiveness ◽

Mixed Treatment Comparison ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Treatment Comparison ◽

Mixed Treatment ◽

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer

JAMA Oncology ◽

10.1001/jamaoncol.2020.1796 ◽

2020 ◽

Vol 6 (8) ◽

pp. 1203

Author(s):

Javier Cortés ◽

Véronique Diéras ◽

Sylvie Lorenzen ◽

Filippo Montemurro ◽

Jorge Riera-Knorrenschild ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Efficacy And Safety ◽

Her2 Positive ◽

Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs20-ot-28-03 ◽

2021 ◽

Author(s):

Geoffrey J Lindeman ◽

Erika Hamilton ◽

Ian Krop ◽

Bora Lim ◽

Shanu Modi ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Controlled Study ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase Ib ◽

Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study

10.1158/1538-7445.sabcs18-ot2-07-03 ◽

2019 ◽

Cited By ~ 1

Author(s):

S Verma ◽

J Shahidi ◽

C Lee ◽

K Wang ◽

J Cortes

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3

102P Phase 3 Study Of Nktr-102 Versus Treatment of Physician's Choice (Tpc) in Patients (Pts) with Locally Recurrent or Metastatic Breast Cancer (Mbc) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Atc)

Annals of Oncology ◽

10.1016/s0923-7534(19)65753-4 ◽

2012 ◽

Vol 23 ◽

pp. ii43-ii44

Author(s):

J. Cortes ◽

E. Perez

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 3 ◽

Previously Treated ◽

Locally Recurrent ◽

Versus Treatment